Business Description
Pulmatrix is a US-based drug development company working on inhaled treatments for respiratory conditions and migraines. Its core technology is a dry powder platform called iSPERSE, which delivers medication directly to the lungs through inhalation. The company has several drugs in clinical development, including treatments for chronic obstructive pulmonary disease, a fungal lung condition affecting asthma and cystic fibrosis patients, and acute migraines. Founded in 2003 and based in Framingham, Massachusetts, Pulmatrix also holds a licensing agreement with RespiVert Ltd. for access to a range of kinase inhibitor compounds.
